Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FMT for Gut Microbiome Diversity in HCT Recipients
NCT03720392Phase 2Terminated
- Start
- Jan 2019
- Primary completion
- May 2020
- Modality
- Live Biotherapeutic Products
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of allogeneic fecal microbiota in graft-versus-host disease (GVHD). Primary endpoint: Proportion of Patients Who Achieve Gut Microbiome Diversity at 1 month. Started Jan 2019; status: terminated.
02
Drugs
allogeneic fecal microbiota
03
Conditions
graft-versus-host disease (GVHD)
Beyond the preview
Go deeper on NCT03720392.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03720392.